Exploring Alzheimer Molecular Pathology in Down's Syndrome Cerebrospinal Fluid | Zendy

Erik Portelius | Zendy; Hilkka Soininen | Zendy; Ulf Andréasson | Zendy; Henrik Zetterberg | Zendy; Rita Persson | Zendy; Gösta Karlsson | Zendy; Kaj Blennow | Zendy; SannaKaisa Herukka | Zendy; Niklas Mattsson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Exploring Alzheimer Molecular Pathology in Down's Syndrome Cerebrospinal Fluid

Author(s) -

Erik Portelius,

Hilkka Soininen,

Ulf Andréasson,

Henrik Zetterberg,

Rita Persson,

Gösta Karlsson,

Kaj Blennow,

SannaKaisa Herukka,

Niklas Mattsson

Publication year - 2014

Publication title -

neurodegenerative diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.98

H-Index - 57

eISSN - 1660-2862

pISSN - 1660-2854

DOI - 10.1159/000358800

Subject(s) - cerebrospinal fluid , microglia , biomarker , amyloid precursor protein , alzheimer's disease , medicine , amyloid (mycology) , endocrinology , pathology , biology , inflammation , disease , biochemistry

Individuals with Down's syndrome (DS) develop early Alzheimer's disease (AD) with β-amyloid (Aβ) plaque pathology. The extra amyloid precursor protein (APP) gene copy in DS is believed to result in a 50% increase in Aβ production, but it is unclear how this relates to the development of other AD hallmarks, including axonal degeneration and microglia cell activation, and to other neurological problems in DS, including disturbed sleep regulation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research